机构：[1]Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China[2]School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China[3]Department of Clinical Laboratory, Molecular Epidemiology Laboratory, Harbin Medical University Cancer Hospital, Harbin 150040, Heilongjiang, China[4]Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China[5]Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, China
The genetic etiology of sporadic neuroblastoma remains largely obscure. RAN and RANBP2 genes encode Ras-related nuclear protein and Ran-binding protein 2, respectively. These two proteins form Ran-RanBP2 complex that regulate various cellular activities including nuclear transport. Aberrant functions of the two proteins are implicated in carcinogenesis. Given the unknown role of RAN/RANBP2 single nucleotide polymorphisms (SNPs) in neuroblastoma risk, we performed a multi-center case-control study in Chinese children to assess the association of the RAN/RANBP2 SNPs with neuroblastoma risk. We analyzed three potentially functional SNPs in RAN gene (rs56109543 C>T, rs7132224 A>G, rs14035 C>T) and one in RANBP2 (rs2462788 C>T) in 429 cases and 884 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to access the association between these four polymorphisms and neuroblastoma risk. No single variant was found to statistically significantly associate with neuroblastoma risk. However, individuals with 3 protective genotypes were less likely to develop neuroblastoma, in comparison to non-carriers (adjusted OR=0.33; 95% CI=0.12-0.96; P=0.042), as well as those with 0-2 protective genotypes (adjusted OR=0.33; 95% CI=0.11-0.94; P=0.038). Stratified analysis revealed no significant association for any of the four polymorphisms. Further studies are warranted to validate the weak impact of RAN/RANBP2 SNPs on neuroblastoma risk.
基金：
This work was supported by grants from the Pearl River
S&T Nova Program of Guangzhou (No:
201710010086), Scientific Research Foundation of
Wenzhou (No: 2015Y0492), Zhejiang Provincial
Medical and Health Science and Technology plan (No:
2009A148), and Zhejiang Provincial Science and
Technology Animal Experimental Platform Project (No:
016C37113).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区生物
小类|3 区细胞生物学
最新[2025]版：
无
第一作者：
第一作者机构：[1]Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China[5]Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, China
推荐引用方式(GB/T 7714)：
Juxiang Wang,Zhenjian Zhuo,Min Chen,et al.RAN/RANBP2 polymorphisms and neuroblastoma risk in Chinese children: a three-center case-control study.[J].Aging.2018,10(4):808-818.doi:10.18632/aging.101429.
APA：
Juxiang Wang,Zhenjian Zhuo,Min Chen,Jinhong Zhu,Jie Zhao...&Haixia Zhou.(2018).RAN/RANBP2 polymorphisms and neuroblastoma risk in Chinese children: a three-center case-control study..Aging,10,(4)
MLA：
Juxiang Wang,et al."RAN/RANBP2 polymorphisms and neuroblastoma risk in Chinese children: a three-center case-control study.".Aging 10..4(2018):808-818
